Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ATF3
REST API REST API
Homo sapiens
ATF3 is differentially expressed in 355 experiments: 128 organism parts: bone marrow, placenta, ... (126 more);, 151 disease states: normal, glioblastoma, ... (149 more);, 102 cell types 355 cell lines 67 compound treatments and 73 other conditions.
Orthologs E1C5C1_CHICK (Gallus gallus)   ATF3_BOVIN (Bos taurus)   Atf3 (Mus musculus)   F6WD51_CIOIN (Ciona intestinalis)   atf3 (Danio rerio)   Atf3 (Rattus norvegicus)   Atf3 (Drosophila melanogaster)   atf3 (Xenopus laevis)   ATF3 (Canis familiaris)   (Compare orthologs)
InterPro Term bZIP_1, bZIP_2, Leuzip_Fos, TF_bZIP
Gene Ontology Term DNA binding, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, transcription, DNA-dependent, positive regulation of cell proliferation, transcription corepressor activity, gluconeogenesis, sequence-specific DNA binding, identical protein binding, protein dimerization activity, nucleus, nucleoplasm, nucleolus, sequence-specific DNA binding transcription factor activity
UniProt Accession Q8WYM6, P18847, Q5VTZ2, Q5VTZ4, Q6ICQ9, Q8NG55, Q7Z566
Search EB-eye ENSG00000162772
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (41 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081, E-GEOD-5823
A549
2
E-GEOD-6013, E-GEOD-3202
BT-474
2
E-GEOD-5823, E-GEOD-3529
DU145
2
E-GEOD-17482, E-GEOD-20089
HL-60
2
E-MTAB-37, E-GEOD-24147
HT1080
2
E-MTAB-37, E-GEOD-20089
349 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-500, E-GEOD-21668, E-GEOD-3920, ... (49 experiments)

Factor Value U/D Experiments
monocyte
4
E-GEOD-11755, E-GEOD-5099, E-MEXP-583, E-GEOD-995
fibroblast
3
E-GEOD-26672, E-GEOD-3920, E-GEOD-3204
macrophage
3
E-GEOD-3982, E-GEOD-5099, E-GEOD-360
human embryonic stem cell
2
E-GEOD-18265, E-GEOD-18147
induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
mononuclear cell
2
E-GEOD-7307, E-GEOD-6053
96 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-TABM-15, ... (66 experiments)

Factor Value U/D Experiments
glioblastoma
1
4
E-GEOD-4290, E-MTAB-62, E-GEOD-6014, E-MEXP-567, E-GEOD-4412 ... (5 experiments)
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-1880
breast cancer
2
E-MTAB-62, E-GEOD-22544
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
control
2
E-GEOD-20602, E-GEOD-21912
obesity
2
E-MTAB-62, E-GEOD-2508
145 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-1417, E-GEOD-5741, E-GEOD-5542, E-TABM-782, ... (39 experiments)

Factor Value U/D Experiments
none
6
11
E-TABM-782, E-MEXP-1958, E-MEXP-1230, E-GEOD-1417, E-GEOD-6907, ... (17 experiments)
lipopolysaccharide
3
E-MEXP-1958, E-TABM-868, E-GEOD-2706
control
2
E-GEOD-4567, E-GEOD-3284
hydroxyurea
1
E-GEOD-6431
ox-LDL
1
E-GEOD-5741
control - interferon-gamma
1
E-GEOD-7216
61 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
81
2
1
E-GEOD-21653


Age years
studied in E-TABM-783

Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (11 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-19246, ... (11 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (7 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-GEOD-2509, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-1923, E-GEOD-17476, E-GEOD-3624, E-TABM-868, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (29 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-GEOD-6927, ... (10 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-GEOD-2487, ... (7 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400, ... (6 experiments)

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16193, E-GEOD-16837, E-MEXP-973, ... (9 experiments)

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Tumor size
studied in E-GEOD-8167

Processing time: 0.393 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM